Navigation Links
CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
Date:3/26/2008

More Than 5,000 Lung Cancer Patients Treated With CyberKnife System to Date

SUNNYVALE, Calif., March 26 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that approximately 90 percent of CyberKnife centers worldwide are now treating lung cancer with the CyberKnife(R) Robotic Radiosurgery System*. The number of lung cancer patients is growing significantly as well, with more than 5,000 individuals receiving CyberKnife treatments to date.

Lung cancer deaths are predicted to increase dramatically, according to a recent report from the World Health Organization (WHO). Lung cancer is expected to become more prominent in the underdeveloped world as a result of an anticipated rise in the use of tobacco products, which is the primary cause of approximately 80 percent of all lung cancer. The WHO "Report On The Global Tobacco Epidemic" projects that lung cancer incidence will increase from 18 million cases in the 20th century to 180 million cases in the 21st century worldwide. The majority of lung cancer cases are expected to be concentrated in 10 countries: China (30 percent of all cases), India (10 percent), Indonesia, Russia, the United States, Japan, Brazil, Bangladesh, Germany and Turkey.

"CyberKnife represents an important advance in the treatment of lung cancer. The CyberKnife System's unparalleled accuracy allows me to offer an effective, non-invasive treatment option for patients with early-stage lung cancer who are not good candidates for surgery," Richard Whyte, M.D., professor of cardiothoracic surgery at Stanford University Medical Center.

In many cases, patients with lung cancer also suffer from other medical conditions that could preclu
'/>"/>

SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
2. Varian Medical Systems Receives FDA 510(k) Clearance for High-Definition Collimator That Enables Ultra-Fine Intensity-Modulated Radiosurgery
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
10. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
11. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... N.J. , May 30, 2015  Data ... 2 MMY2002 (SIRIUS) trial show treatment with single-agent ... – achieved an overall response rate (ORR) of ... an independent review committee, in heavily pre-treated patients ... the pre-specified subgroups based on age, prior lines ...
(Date:5/29/2015)... 29, 2015 BerGenBio AS ("BerGenBio" ... that an abstract on the latest data on BGB324, ... Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking ... published in conjunction with the 2015 American Society of ... , May 29 - June 2, 2015. ...
(Date:5/29/2015)... London, UK (PRWEB) May 29, 2015 ... Co., Ltd. (Chem-Report ) signed a partnership agreement ... is now authorised to distribute and sell research ... Assistant Manager at Partners Department, commented upon the ... creating reports on key petroleum and chemical markets ...
(Date:5/29/2015)... , May 29, 2015  Caris Life ... on fulfilling the promise of precision medicine, today ... that demonstrate the clinical utility of Caris Molecular ... profiling service, in helping to identify targeted treatment ... In each of the studies, results of which ...
Breaking Biology Technology:Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6
... NEW YORK and MONTREAL, Dec. 21 /PRNewswire-FirstCall/ - ICBS Ltd. ... state and municipal regulatory bodies for the sale of the ... Solutions will be moving to target regulatory agencies in the ... advantages not only on time advantage (10 Hours for test ...
... III trials of OGX-011 in first- and second-line advanced ... begin in 2010 and early 2011 -- , -- ... to target resistance to cancer treatments -- , JERUSALEM, ... - Teva Pharmaceutical Industries Ltd. ( TEVA) and OncoGenex ...
... , , THOUSAND OAKS, Calif., Dec. ... Roger M. Perlmutter, M.D., Ph. D., Amgen,s executive vice ... Fellow of the American Association for the Advancement of Science ... on behalf of the advancement of science or its applications ...
Cached Biology Technology:BioSpec Global Solutions Inc. target market TOGS 9000 to state and municipal regulatory bodies in U.S. market 2Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 2Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 3Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 4Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 5Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 6Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 7Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 8Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines 2Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines 3
(Date:5/11/2015)... a well-rounded UAS delegation representing private industry, government, and academia, ... AUVSI,s Unmanned 2015 conference last week in Atlanta ... UAS industry met with over 200 hundred people from companies ... ecosystem. "Our message is clear and consistent," ... Rich Knoll . "If you want to fly UAS, you ...
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... 2008Systems biology scientists from diverse areas of research are ... data, and derive therapeutic targets from biological networks, reports ... point of much of the work is to characterize ... complex biological networks, according to an article in the ...
... Louise Brown the first baby conceived by in ... a new book coauthored by a Rutgers medical historian ... John Rock, the Harvard-affiliated gynecologist and pioneering researcher, in ... was the first researcher to fertilize a human egg ...
... UK Office to Meet Increased Demand for Secure and Managed USB ... Memory Sticks ... the,world,s most secure flash drive, today announced that the company has,opened a ... more worldwide markets. IronKey,s new office will help support its,rapid growth in ...
Cached Biology News:Rutgers scholar authors definitive biography of reproductive medicine pioneer 2IronKey Opens New European Office 2
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... Kit provides a positive selection for creating ... expression in insect cells. The kit improves ... baculoviruses by eliminating the time-consuming steps of ... AcNPV genome with a portion of the ...
... General description: Dish uses include large-scale ... Compatible with PBA Flexys TM automated ... number is a new product number, created ... showing no availability yet, please order under ...
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Biology Products: